MindWalk (NASDAQ:HYFT) Downgraded by Zacks Research to Strong Sell

MindWalk (NASDAQ:HYFT) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

HYFT has been the subject of a number of other research reports. JonesTrading initiated coverage on MindWalk in a research report on Thursday, April 16th. They set a “buy” rating and a $5.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Finally, Wall Street Zen lowered shares of MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, MindWalk currently has a consensus rating of “Hold” and an average target price of $5.00.

MindWalk Stock Performance

Shares of NASDAQ:HYFT opened at $1.33 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. The company’s fifty day moving average is $1.56. The firm has a market cap of $62.36 million, a PE ratio of -6.07 and a beta of 0.83. MindWalk has a one year low of $0.99 and a one year high of $3.25.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The company had revenue of $3.03 million during the quarter. As a group, equities research analysts predict that MindWalk will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MindWalk

Several institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can lifted its position in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the period. Renaissance Technologies LLC boosted its stake in MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after buying an additional 18,600 shares during the last quarter. Jane Street Group LLC grew its holdings in MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after buying an additional 96,018 shares during the period. Bridgeway Capital Management LLC acquired a new position in shares of MindWalk during the 4th quarter valued at about $91,000. Finally, XTX Topco Ltd increased its stake in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares during the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.